Search
Clopenthixol
go.drugbank.com/drugs/DB13841InvestigationalClopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Ocadusertib
go.drugbank.com/drugs/DB21732InvestigationalOcadusertib has a monoisotopic molecular weight of 459.19 Da. … Ocadusertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Ocadusertib is a serine/threonine kinase inhibitor.
Chromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: One-A-day Advance Men's, Great Day/am Formula TabCategories: Compounds used in a research, industrial, or household settingVidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the … A nucleoside antibiotic isolated from Streptomyces antibioticus.
Synonyms: 9-β-D-arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-adenineInternational brands: Arasena-ATasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalOccurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA.
Dichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market
Synonyms: DCALecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology
Deferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Compounds used in a research, industrial, or household settingProducts: DEFERASIROX TEVA GENERICS